FORTRESS BIOTECH, INC.

Analyst Reco. Fortress Biotech, Inc. Nasdaq

Equities

FBIOP

US34960Q2084

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
16.67 ^USD	+1.96%		+4.32%	+40.44%

05-15	Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	MT
05-14	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	03-19	MT
Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	11-29	MT
B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating	23-08-22	MT
Cantor Fitzgerald Lowers Price Target on Fortress Biotech to $5 From $6, Maintains Overweight Rating	23-05-16	MT
Ladenburg Thalmann Starts Fortress Biotech at Buy With $6 Price Target	22-08-04	MT
B. Riley Securities Lowers Fortress Biotech's Price Target to $6 from $8, Keeps Buy Rating	22-07-14	MT
Benchmark Capital Adjusts Fortress Biotech's Price Target to $5 from $8, Keeps Buy Rating	22-03-29	MT
FORTRESS BIOTECH : B. Riley Lowers Fortress Biotech's PT to $8 from $9, Says Incremental Pipeline Updates Suggest Heightened Focus on Next-Gen Therapies; Keeps Buy Rating	21-06-17	MT
FORTRESS BIOTECH : Roth Capital Adjusts Price Target on Fortress Biotech to $5 From $4.50, Maintains Buy Rating	21-04-20	MT
FORTRESS BIOTECH : B. Riley Raises Fortress Biotech's Price Target to $9 from $8 After 'Strong' Q4 2020 Results, Keeps Buy Rating	21-04-05	MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage	18-08-02	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW